Multiple Myeloma News

Here are all the latest news articles written by The Beacon’s staff.

For news articles about treatments commonly given to myeloma patients, click on these links:
bisphosphonates, KyprolisPomalyst (Imnovid), Revlimid, thalidomide, Velcade, and Zometa.

For news articles about potential new myeloma treatments, click on these links:
ARRY-520 (filanesib), ACY-1215 (rocilinostat), afuresertib (GSK2110183), BT-062, daratumumab, elotuzumab, ixazomib (MLN9708),  marizomib (NPI-0052), MOR202, oprozomib, panobinostat, SAR650984, Treanda (bendamustine), and Zolinza (vorinostat).

For news articles about specific myeloma-related topics, click on these links:
bone disease, kidney failure, MGUS, maintenance therapy, peripheral neuropathysecondary cancer, smoldering multiple myeloma, and stem cell transplants.

[ by | Jul 23, 2014 2:56 pm | 12 Comments ]
The Myeloma Quiz – July 2014

It’s July, and we have had some time to digest the findings from the American Society of Clinical Oncology (ASCO) annual meeting held in Chicago May 30 through June 3.

Quite a few presentations caught one’s eye.

We finally saw the results of the much awaited PANORAMA-1 study in­ves­ti­gating the efficacy and safety of panobinostat (LBH589) plus Velcade and dexa­meth­a­sone compared to Velcade and dexamethasone alone.

Exciting data on the CD38 antibodies daratumumab and SAR650984 continued to emerge at ASCO.

Another study looked at …

Read the full story »
[ by | Jul 16, 2014 8:54 am | 39 Comments ]
Treatment Regimen Featuring Revlimid-Velcade-Dexamethasone Therapy And Stem Cell Transplantation Yields Deep Responses In Newly Diagnosed Multiple Myeloma

French researchers earlier this week published updated results of a small Phase 2 clinical trial testing the combination of Revlimid, Velcade, and dexa­metha­sone (RVD) in newly diagnosed multiple myeloma pa­tients.

The researchers found that RVD, when given before and after stem cell trans­plan­ta­tion – and when followed by maintenance therapy with Rev­limid – led to very deep treatment responses and significant survival rates.

The 31 newly diagnosed patients in the French trial initially were treated with three cycles of RVD therapy.  Next, the trial participants underwent autologous (own) stem cell …

Read the full story »
[ by | Jul 12, 2014 2:41 pm | 8 Comments ]
The Neglected Common Thread: Malaria Drugs As Potential Myeloma Therapies

One of the first recorded cases of multiple myeloma in the modern era was that of Thomas Alexander McBean.

McBean was a well-to-do grocer in London who, in 1844, developed a condition which at the time had no name and no known cause.

It is now known, however, that what McBean had was multiple myeloma. This has been determined, in part, through work done by Dr. Henry Bence Jones in analyzing a sample of McBean’s urine — work which led to the identification of what is now described as …

Read the full story »
[ by | Jun 26, 2014 1:06 pm | 14 Comments ]
Highlights Of The 2014 International Myeloma Working Group Annual Summit

The 2014 International Myeloma Working Group (IMWG) Annual Summit took place in Milan, Italy on June 9 and 10.

The summit is a special meeting organized by the International Myeloma Foun­da­tion in which leading myeloma researchers get to brainstorm col­lectively about the most pressing issues in the field, find ways to col­lab­o­rate, and plan future laboratory and clinical studies.

The IMWG summit is hailed by most attendees as the most important meeting for myeloma researchers worldwide. It is a unique opportunity for investigators in the field to engage in lively …

Read the full story »